Spots Global Cancer Trial Database for Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Official Title: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Study ID: NCT03126110
Study Description
Brief Summary: The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Angeles Clinic and Research Institute, Los Angeles, California, United States
University of Florida, Gainesville, Florida, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Washington University - Siteman Cancer Center, Saint Louis, Missouri, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Memorial Sloan Kettering Cancer, New York, New York, United States
The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
University of Oklahoma, Sarah Cannon Research Institute, Oklahoma City, Oklahoma, United States
Providance Portland Medical Center, Portland, Oregon, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
University of Pittsburgh, UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, United States
Tennessee Oncology, Sarah Cannon Research Institute, Nashville, Tennessee, United States
BUMC Mary Crowley Cancer Research Centers, Dallas, Texas, United States
MD Anderson, Houston, Texas, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
Scientia Clinical Research, Randwick, New South Wales, Australia
Greenslopes Private Hospital, Brisbane, Queensland, Australia
Austin Hospital, Heidelberg, Victoria, Australia
Linear Clinical Research, Perth, Western Australia, Australia
CHA Centre Hospitalier de l'Ardenne, Libramont, Chevigny, Belgium
Saint Augustinus Hospital, Antwerpen, , Belgium
Institut Jules Bordet, Brussels, , Belgium
Cliniques Universitaires Saint-Luc, Brussels, , Belgium
CHU Brugmann, Bruxelles, , Belgium
Mi Kryviy Rih Center of Dnipropetrovsk Regional Council, Charleroi, , Belgium
Ghent University Hospital, Ghent, , Belgium
AZ Groeninge, Kortrijk, , Belgium
Hospital Clinic I Provincial, Barcelona, , Spain
Hospital Clinico y Provincial de Barcelona, Barcelona, , Spain
Institut Catala D'Oncologia-Badalona, Barcelona, , Spain
Hospital Vall de Hebron, Barcelona, , Spain
Hospital Reina Sophia, Córdoba, , Spain
University Hospital Ramon y Cajal, Madrid, , Spain
Hospital Universitario Doce de Octubre, Madrid, , Spain
Hospital HM Sanchinarro, Madrid, , Spain
Clinica Universidad De Navarra (CUN), Pamplona, , Spain
Hospital Universitario Virgen Del Rocio, Sevilla, , Spain
Contact Details
Name: John E. Janik, MD
Affiliation: Incyte Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
